Yann Godbert
Yann Godbert is an expert in Endocrinology at Institut Bergonié (France). Yann Godbert has authored 87 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 1 of them ongoing. SLR score: 416 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Oncology - Nuclear Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Institut Bergonié
2013 - 2026
Number : 87
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Lymphopenia and Circulating Biomarker Dynamics Associated with Clinical Outcome and Toxicity in Pazopanib-Treated Radioiodine-Refractory Thyroid Cancer: Exploratory Analyses from the Pazothyr Trial. PMID 43007078 — cytokines, cells, thyroid diseases, growth, vascular endothelial growth factor a, lymphopenia, neoplasms, interleukin-6, thyroid gland, biomarkers, thyroid neoplasms, therapeutics, thyroid hormones, plasma | Thyroid | 2026 | 0 |
| Real-World Outcomes of [ 177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer. PMID 42562607 — safety, androgens, receptors, androgen, neoplasms, prostate, drug therapy, aged, neoplasm metastasis, prostatic neoplasms, castration, therapeutics, chemotherapy | J Nucl Med | 2026 | 0 |
| Complete Radiologic Response After 177Lu-DOTATATE Therapy in Treatment of a Lung Metastatic Intracranial Atypical Meningioma. PMID 40739709 — lung, somatostatin, meningioma, therapeutics | Clin Nucl Med | 2025 | 0 |
| ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer. PMID 40345488 — endocrinology, neoplasms, thyroid gland, thyroid neoplasms, therapeutics | Ann Endocrinol (Paris) | 2025 | 0 |
| ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer. PMID 40288439 — endocrinology, neoplasms, multiple chronic conditions, thyroid gland, thyroid neoplasms, therapeutics, prognosis | Ann Endocrinol (Paris) | 2025 | 1 |
Clinical Studies 14
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Intra arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP NET Patients With Dominant Liver Metastases NCT04837885 — injections, somatostatin, tomography, administration, intravenous, positron-emission tomography, neoplasms, positron emission tomography computed tomography, liver, liver neoplasms, neoplasm metastasis, neuroendocrine tumors, therapeutics, receptors, peptide, injections, intravenous | Phase 2 | Recruiting | 2021 |
LeadR Networks
Main global connection map